What’s BMS saying about its Celgene buy behind the scenes? This transcript tells all
Bristol-Myers Squibb CEO Giovanni Caforio has friends on TV now. R&D chief Tom Lynch has done some of his CAR-T due diligence on YouTube. And one reason Celgene was interested in Bristol’s $ 74 billion buyout bid is that its own rollout of multiple sclerosis drug Otezla was, well, pretty lame. A fly on the… Read More »
